Clinical trials: Ventilator Associated Pneumonia ( VAP)
Ventilator-associated Pneumonia
B Lymphocyte Populations in the Pulmonary Microenvironment of Patients Under Mechanical Ventilation With or Without VAP (Ventilator-Associated Pneumonia)
Diagnosis of VAP relies on a set of non-specific clinical, biological, and imaging criteria. Understanding host-pathogen interactions and the mechanisms of deregulations leading to infection of pulmonary tissue appears essential.
- Trial name
- OLYMPE (NCT07436780)
- Where
- France
- Volunteers
- 75 people
- Sponsor
- University Hospital, Limoges
Ventilator Associated Pneumonia
Role of Lactoferrin in Prevention of Ventilator Associated Pneumonia in Neonates.
The aim of the study is to 1. Evaluate the preventive value of Lactoferrin on VAP among ventilated neonates. 2. Evaluate the Primary outcome of Lactoferrin on: Sepsis, Feeding intolerance, Vomiting, Constipation or diarrhea 3.
- Trial name
- NCT07255742
- Testing
- Lactoferrin in prevention of VAP, Control
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Dalia Mohamed Salah
Ventilator Associated Pneumonia, Infection
Probiotic Prophylaxis for Microbiome Modulation and VAP or Infections Prevention in Multitrauma Patients
Ventilator-associated pneumonia (VAP), is a type of pneumonia that develops more than 48 hours after endotracheal intubation, is common in intensive care units (ICUs).
- Conditions
- Ventilator Associated Pneumonia, Infection, Trauma
- Trial name
- NCT03074552
- Testing
- LactoLevure
- Where
- Greece
- Volunteers
- 112 people
- Sponsor
- Aristotle University Of Thessaloniki
Ventilator Associated Pneumonia
Study of Knowledge Translation of Clinical Practice Guidelines for Ventilator Associated Pneumonia
The purpose of this prospective, multicentre, time-series study is to develop, implement, refine, and evaluate a sustainable behaviour change strategy in the intensive care unit (ICU).
- Trial name
- ABATEVAP (NCT00434460)
- Testing
- Education
- Where
- 11 sites in United States, Canada
- Volunteers
- 1,320 people
- Sponsor
- Canadian Critical Care Trials Group
Mechanical Ventilation Pressure High, Ventilator-Associated Pneumonia (VAP)
Dynamic Airway Resistance & ML: Guide Sputum Suction in Ventilated Patients
Research has shown that timely suctioning not only improves survival rates but also enhances the quality of life in ventilator-dependent patients.
- Conditions
- Mechanical Ventilation Pressure High, Ventilator-Associated Pneumonia (VAP), Respiratory Depression Neonatal
- Trial name
- NCT07375667
- Testing
- The dynamics of airway resistance, conventional suctioning
- Where
- 3 sites in China
- Volunteers
- 258 people
- Sponsor
- Affiliated Hospital of Nantong University
VAP - Ventilator Associated Pneumonia
Microbiological Profile of VAP Patients in Respiratory ICU
Identification of the microbial profile of Ventilator associated pneumonia causing microorganisms among Respiratory ICU patients .
- Trial name
- VAP (NCT05738928)
- Testing
- blood and sputum culture
- Volunteers
- 86 people
- Sponsor
- Assiut University
Sepsis, Ventilator-Associated Pneumonia
Diagnostic Value of sTREM-1 and PCT Level as Well as CPIS Score for Ventilator-Associated Pneumonia Among ICU Sepsis Patients
Aims: to explore the value of TREM-1 (triggering receptor expressed on myeloid cells-1) ,PCT(Procalcitonin), as well as CPIS (clinical pulmonary infection score) in the diagnostic and prognostic assessment of VAP (ventilator…
- Trial name
- NCT01406951
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Chinese PLA General Hospital
Ventilator Associated Pneumonia
GRam Stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) Trial
Background: Optimising the use of antibiotic agents is a pressing challenge to overcoming the rapid emergence and spread of multidrug-resistant pathogens in intensive care units (ICUs).
- Trial name
- NCT03506113
- Testing
- Gram stain-guided antibiotic choice, Guidelines-based antibiotics choice
- Where
- 12 sites in Japan
- Volunteers
- 206 people
- Sponsor
- Osaka General Medical Center
Ventilator Associated Pneumonia (VAP), Evidence Based Practice
Effect of Implementing Evidence-based Practice and Nurse's Behavior Change on Quality of Care in Intensive Care Unit: Focus on Ventilator Associated Pneumonia in a Tertiary Hospital in Bangladesh
Quality of care is crucial for preventing adverse events such as infection in the intensive care units (ICUs). The most common ICU-acquired infections include pneumonia such as ventilator-associated pneumonia (VAP), Central Line…
- Trial name
- EBP in Nursing (NCT06624540)
- Testing
- This is a pre- and post- quasi-experimental study., Education with EBP
- Where
- 2 sites in Bangladesh, Japan
- Volunteers
- 272 people, healthy volunteers welcome
- Sponsor
- Hiroshima University
Hospital-acquired Pneumonia (HAP), Ventilator-Associated Pneumonia (VAP)
Resistance-Optimised Antimicrobial Dosing in Critically Ill Patients, a Randomised Controlled Trial
Critically ill people who need a breathing machine often develop hospital-acquired lung infections. These infections are commonly treated with the antibiotics piperacillin/tazobactam or meropenem.
- Conditions
- Hospital-acquired Pneumonia (HAP), Ventilator-Associated Pneumonia (VAP), Nosocomial Respiratory Infection, Critical Illness
- Trial name
- ROAD-RCT (NCT07820501)
- Testing
- Resistance-Optimised Precision Dosing, Standard Care Dosing
- Volunteers
- 610 people
- Sponsor
- The University of Queensland
Complicated Intra-Abdominal Infections, cIAIs, Hospital-acquired Pneumonia (HAP)
Real-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CRE
Why This Study is Needed Some bacterial infections have become resistant to common antibiotics, making them very difficult to treat. This is a growing and serious health problem.
- Conditions
- Complicated Intra-Abdominal Infections, cIAIs, Hospital-acquired Pneumonia (HAP), Ventilator-Associated Pneumonia (VAP)
- Trial name
- AWARE (NCT07268560)
- Testing
- Aztreonam-Avibactam
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Sir Run Run Shaw Hospital
Ventilator-Associated Pneumonia (VAP), Neonatal, Bronchopulmonary Dysplasia (BPD)
National Surveillance and Prevention of Neonatal VAP
The goal of this observational study is to improve how hospital-acquired lung infections (called ventilator-associated pneumonia, or VAP) are diagnosed, treated and prevented in very low birth weight (VLBW) infants, babies born…
- Conditions
- Ventilator-Associated Pneumonia (VAP), Neonatal, Bronchopulmonary Dysplasia (BPD), Antibiotic-Resistant Organisms (AROs), Health-Care Associated Infection (HAI)
- Trial name
- NCT07109791
- Where
- Canada
- Volunteers
- 1,500 people
- Sponsor
- University of Alberta
Pneumonia, Ventilator-Associated
Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus
Ventilator-associated pneumonia (VAP) is a commonplace complication of intensive care patients ventilated for longer than 48 hours.
- Trial name
- NCT00572559
- Testing
- Vancomycin, Linezolid
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 149 people
- Sponsor
- Pfizer
Ventilator-Associated Pneumonia (VAP)
Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial
Previous studies have identified Acinetobacter baumannii (AB), Pseudomonas aeruginosa (PA), and Klebsiella pneumoniae (KP) as the predominant pathogens responsible for ventilator-associated pneumonia (VAP).
- Trial name
- CIVAP (NCT06834971)
- Testing
- Colistimethate sodium (CMS)
- Where
- China
- Volunteers
- 508 people
- Sponsor
- Qilu Hospital of Shandong University
Lung Infection, Pneumonia, Ventilator-Associated
Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301
AR-301 is being evaluated as an adjunctive treatment of ventilator-associated pneumonia (VAP) due to Staphylococcus aureus (S. aureus) in combination with standard of care (SOC) antibiotic therapy in patients with confirmed S.
- Conditions
- Lung Infection, Pneumonia, Ventilator-Associated, Infection, Bacterial, Staphylococcus Aureus
- Trial name
- AR-301-002 (NCT03816956)
- Testing
- AR-301
- Where
- 45 sites in Belarus, Belgium and 13 more
- Volunteers
- 174 people
- Sponsor
- Aridis Pharmaceuticals, Inc.
Ventilator Associated Pneumonia (VAP)
Addition of Tobramycin Inhalation in the Treatment of Ventilator Associated Pneumonia
This study evaluates the addition of tobramycin inhalation treatment to standard intravenous therapy in the treatment of ventilator associated pneumonia.
- Trial name
- VAPORISE (NCT02440828)
- Testing
- tobramycin inhalation
- Where
- 2 sites in Netherlands, Spain
- Volunteers
- 80 people
- Sponsor
- Erasmus Medical Center
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI)
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
This study is designed to provide evidence of efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens.
- Conditions
- Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI)
- Trial name
- CREDIBLE - CR (NCT02714595)
- Testing
- Cefiderocol, Best Available Therapy
- Where
- 85 sites in United States, Brazil and 14 more
- Volunteers
- 152 people
- Sponsor
- Shionogi
Ventilator Associated Pneumonia
Perpetual Observational Study - Ventilator Associated Pneumonia
Ventilator-Associated Pneumonia (VAP) is a bacterial respiratory infection that patients in the Intensive Care Unit (ICU) often get when they cannot breathe for themselves and require mechanical ventilation.
- Trial name
- POS-VAP (NCT05719259)
- Where
- 35 sites in Albania, Belgium and 11 more
- Volunteers
- 20,000 people
- Sponsor
- European Clinical Research Alliance for Infectious Diseases (ECRAID)
VAP - Ventilator Associated Pneumonia
LUNG INFECTION IN ICU (LUNG-I3)
objective of LUNG-I3 study is to assess the quantitative and functional differences in cells between blood and bronchoalveolar lavage (BAL) fluid after an infection, with a special focus on alveolar macrophages and neutrophils
- Trial name
- LUNG-I3 (NCT06073834)
- Where
- France
- Volunteers
- 7 people
- Sponsor
- BioMérieux
Ventilator-Associated Pneumonia
Ventilator-Associated Pneumonia (VAP) in Intensive Care Unit (ICU)
Ventilator-associated pneumonia (VAP) is very common in the intensive care unit (ICU), affecting 9 to 40% of ICU patients and mortality rates range from 20 to 50% and may reach more than 70% when the infection is caused by…
- Trial name
- NCT00935285
- Where
- Greece
- Volunteers
- 300 people
- Sponsor
- University of Thessaly